Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".

Mazza, Mario Gennaro; Vai, Benedetta; De Picker, Livia; Benedetti, Francesco; Zanardi, Raffaella

Mazza, Mario Gennaro; Vai, Benedetta; De Picker, Livia; Benedetti, Francesco; Zanardi, Raffaella.

Afiliación

Mazza MG; Psychiatry and Clinical Psychobiology, Division of Neuroscience, Dipartimento di Neuroscienze Cliniche, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy. mazza.mariogennaro@hsr.it.
Vai B; Vita-Salute San Raffaele University, Milan, Italy. mazza.mariogennaro@hsr.it.
De Picker L; Psychiatry and Clinical Psychobiology, Division of Neuroscience, Dipartimento di Neuroscienze Cliniche, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy.
Benedetti F; Vita-Salute San Raffaele University, Milan, Italy.
Zanardi R; University Psychiatric Hospital Campus Duffel, Duffel, Belgium.

Drugs ; 82(3): 349-351, 2022 02.

Article en En | MEDLINE | ID: mdl-35150437

Asunto(s)

Tratamiento Farmacológico de COVID-19; Fluvoxamina; Humanos; SARS-CoV-2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fluvoxamina / Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Drugs Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google